Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001193125-26-059638
Filing Date
2026-02-19
Accepted
2026-02-19 17:00:06
Documents
1
Period of Report
2026-02-18

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3859
  Complete submission text file 0001193125-26-059638.txt   5640
Mailing Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142
Business Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142 617-410-4650
Cullinan Therapeutics, Inc. (Issuer) CIK: 0001789972 (see all company filings)

EIN.: 813879991 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O CULLINAN THERAPEUTICS, INC ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142
Business Address
Savill Corrine (Reporting) CIK: 0001837524 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39856 | Film No.: 26655446